October 25, 2024 07:12 AM EDT
Financing
Startups

Septer­na bags $288M up­sized IPO for GPCR drugs

Kyle LaHucik

Senior Reporter

Nascent clin­i­cal biotech Septer­na added to the slight uptick in IPO fer­vor this fall with its $288 mil­lion Nas­daq list­ing on Fri­day.

In­vestors seemed en­thused …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Sanofi backs fi­bro­sis biotech Agomab as it rais­es $89M Se­ries D

Elu­ci­da On­col­o­gy, seek­ing foothold in AD­Cs, shut­ters due to 'lack of fund­ing'

Sanofi re­ports sales jump for Bey­for­tus as RSV an­ti­body chal­lenger from Mer­ck nears

GSK to spend $800M to build two vac­cine fac­to­ries in the US

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times